Posted onMarch 22, 2016

The Global Hepatitis C Virus (HCV) Market research of 60 pages with 47 Charts and 12 Tables, 4 company profiles to the pharmaceuticals industry segment of its online data and intelligence library.

Hepatitis C Virus (HCV) is an infection which affects the liver which may lead to serious consequences if not taken care of. It spreads through infected blood transfusions and poorly sterilized medical equipments. The number of patients has increased significantly because its symptoms take time to be recognized before the patient progresses towards a clinically visible liver damage which worsens the situation since it may lead to liver damage or even failure. There was no proper therapy for HCV before 2010 but the coming of therapies like Sovaldi and Harvoni by Gilead and Viekira Pak by AbbVie has improved the scenario. Also the steps taken like proper blood screening is also helping in identifying the patients.

The key factors which are anticipated to drive HCV market include medical reimbursement because of the therapy being very costly, growth in the number of patients, relatively smaller period of drug treatment from before, treatment of the warehoused patients who were waiting for a better therapy and pricing discounts and better regimens because of the increased competition. Some of the significant developments of this industry include launch of the interferon free regimen and development of products like Sovaldi, Harvoni and Viekira Pak and the newly identified and diagnosed patients. However, the challenges to be faced ahead is more number of patients asking for reimbursement, increasing competition leading to price cutting, risk associated with drug development and regulatory risk.

This report offers a comprehensive analysis of the HCV market. Furthermore, market dynamics such as key trends and development; and challenges are analyzed in depth. On the contention front, the global HCV market is reined by few major players namely Gilead Sciences, AbbVie, Johnson & Johnson and Bristol-Myers Squibb. The competitive landscape of the respective market, along with the company profiles of the leading players are also discussed in detail.

By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the HCV market. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests.

Types of Hepatitis C Virus (HCV) Natural History of HCV InfectionGlobal HCV Market by Value (2011-2015)HCV Genotype 1 Patients in Emerging Markets (2015)Global Deaths Due to HCV (2010-2014)The US HCV Market by Value (2011-2015)The US HCV Market Dynamics (2014)Total Estimated HCV Patients to be treated in US (2015)Total Estimated Genotype1 Patients to be treated in the US (2015)Estimated HCV Patients to be treated in the US (2016E–2029E)Patients Initiating Treated with Sofosbuvir Based Regimen (2015)HCV Patients Initiated Treatment with Sofosbuvir based Regimen by Genotype (2015)HCV Patients Initiated Treatment with Sofosbuvir based Regimen by Fibrosis Score (2015)HCV Patients Initiated Treatment with Sofosbuvir based Regimen by Patient Type (2015)EU HCV Market by Value (2011-2015)Estimated Number of Patients to be treated in EU (2016E – 2029E)

MarketReportsOnline comprises of an online library of 2,50,000 reports and in-depth market research studies of over 5000+ micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.